Conclusion
Although calcitonin has an established place in the treatment of Paget's disease of bone and certain disorders of calcium homeostasis, its most exciting clinical application is in the management of postmenopausal and senile osteoporosis. This disorder affects a vast number of women and, with the increasingly aging population, imposes a heavy burden on health care systems. Although other therapies for osteoporosis and other disorders of bone turnover (e.g., bisphosphonates, fluoride) are in use, many questions remain to be answered concerning their side effects and long-term safety, whereas salmon calcitonin is of proven safety. The introduction of salmon calcitonin nasal spray is a significant therapeutic advance, and the development of other noninjectable preparations will further increase the acceptability of calcitonin to patients and physicians alike.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Copp DH (1994) Calcitonin: discovery, development, and clinical application. Clin Invest Med 17:268–277
Azria M (1989) The calcitonins: physiology and pharmacology. Karger, Basel
Copp DH, Davidson AGF, Cheney BA (1961) Evidence for a new parathyroid hormone which lowers blood calcium. Proc Can Fed Biol Soc 4:17
Copp DH, Cameron EC, Cheney B, Davidson AGF, Henze K (1962) Evidence for calcitonin—a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70:638–649
Kumar MA, Foster GV, MacIntyre I (1963) Further evidence for calcitonin—a rapid acting hormone which lowers blood calcium. Lancet ii:480–482
Hirsch PF, Gauthier GF, Munson PL (1963) Thyroid hypocalcemic principle and recurrent laryngeal nerve injury as factors affecting the response to parathyroidectomy in rats. Endocrinology 73:244–252
Pearse AGE, Carvalheira AF (1967) Cytochemical evidence for an ultimobranchial origin of rodent thyroid C cells. Nature 214:929–930
Copp DH, Cockcroft DW, Kueh Y (1967) Calcitonin from the ultimobranchial glands of dogfish and chickens. Science 158:924–926
O'Dor RK, Parkes CO, Copp DH (1969) Amino acid composition of salmon calcitonin. Can J Biochem 47:823–825
Niall JT, Keutmann HT, Copp DH, Potts JT Jr (1969) Amino acid sequence of salmon ultimobranchial calcitonin. Proc Natl Acad Sci USA 63:771–778
Guttmann S, Pless J, Huguenin RL, Sandrin E, Bossert H, Zehnder K (1969) Synthese von Salm-Calcitonin, einem hochaktiven hypocalcämischen Hormon. Helv Chim Acta 52:1789–1795
Chambers TJ, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endocrinol Metab 57:819–824
Wallach S, Farley JR, Baylink DJ, Brenner-Gati L (1993) Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 52:335–339
Geusens P, Nijs J, Jiang Y, Caulin F, Van Audekercke R, Van der Perre G, Goovaerts S, Gielen J, Marchal G, Dequeker J (1990) Bone mass, density and strength in ovariectomized sheep treated with salmon calcitonin. In: Christiansen C, Overgaard K (ed) Osteoporosis 1990. Osteopress ApS, Copenhagen, pp 1152–1153
Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 305:556–561
Zanelli JM, Gaines-Das RE, Corran PH (1990) International Standards for salmon calcitonin and the ASU 1–7 analogue of eel calcitonin: calibration by international collaborative study. Bone Miner 11:1–17
Singer FR, Fredericks RS, Minkin C (1980) Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum 23:1148–1154
Patel S, Lyons AR, Hosking DJ (1993) Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs 46:594–617
Sjöberg HE, Hjern B (1975) Acute treatment with calcitonin in primary hyperparathyroidism and severe hypercalcaemia of other origin. Acta Chir Scand 141:90–95
Nishi Y, Hamamoto K, Kajiyama M, Ono H, Kihara M, Jinno K (1992) Effect of long-term calcitonin therapy, by injection and nasal spray on the incidence of fractures in osteogenesis imperfecta. J Pediatr 121 (3): 477–480
Doury P, Dirheimer Y, Pattin S (1981) Algodystrophy: diagnosis and therany of a frequent disease of the locomotor apparatus. Springer, Berlin, Heidelberg, New York
di Perry T, Auteri A, Bruni F, Blardi P, Vannucchi F (1985) Calcitonin treatment for rheumatoid arthritis: a controlled clinical study. In: Pecile A (ed) Calcitonin 1984. Excerpta Medica, Amsterdam, pp 307–314
Miralles FS, Lopez-Soriano F, Puig MM, Perez D, Lopez-Rodriguez F (1987) Postoperative analgesia induced by subarachnoid lidocaine plus calcitonin. Anesth Analg 66:615–618
Becker HD, Reeder DD, Scurry MT, Thompson JC (1974) Inhibition of gastrin release and gastric secretion by calcitonin in patients with peptic ulcer. Am J Surg 127:71–75
Goebell H, Hotz J (1981) Calcitonin, pancreatic secretion and pancreatitis. In: Pecile A (ed) Calcitonin 1980. Excerpta Medica, Amsterdam, pp 346–351
Franchi F, Chiarini P, Matassi L, Strazzulla G, Scardi A, Righi D, Nuzzaci D (1983) Effect of calcitonin on limb blood vessels in human obstructive arterial disease. Int J Clin Pharm Res 111 (2):115–128
Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989a) Effect of calcitonin given intranasally on early postmenopausal bone loss. Br Med J 299:477–479
Reginster JYL, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I (1995) A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumber spine bone loss. Am J Med 98:452–458
Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989b) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435–442
Mazzuoli GF, Tabolli S, Bigi F, Vatorta C, Diacinti D, Scarnecchia L, Minisola S, Bianchi G, Piolini M, Dell' Acqua S (1989) Effects of salmon calcitonin on loss of bone mass induced by ovariectomy: controlled double-blind study. In: Mazzuoli GF (ed) Calcitonin ′88. Proc Int Symp. Sandoz Ltd, Basel, pp 15–24
Overgaard K, Hansen MA, Nielsen VAH, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis—effects of withdrawal of treatment. Am J Med 89:1–6
Minaire P, Mallet E, Levernieux J, Schoutens A, Attali G, Caulin F (1987) Immobilization bone loss: preventive effects of calcitonin in several models. In: Christiansen C, Johansen JC, Riis BJ (eds) Osteoporosis 1987. Osteopress ApS, Copenhagen pp 603–610
Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 33:35–39
Ringe JD (1990) Intranasal salmon calcitonin in the treatment of steroid-induced osteoporosis. In: Christiansen C, Overgaard K (eds) Osteoporosis 1990. Osteopress ApS. Copenhagen, pp 1868–1871
Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Lopez Vas AA, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribor C (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 305:1124–1128
Rico H, Hernandez ER, Revilla M, Gomez-Castresana F (1992) Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131–138
Pun KK, Chan LWL (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205–209
Gennari C, Agnusdei D, Camporeale A (1991) Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49 (suppl 2):S9–13
Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268–1274
Gennari C, Passeri M, Chierichetti SM, Piolini M (1983) Side effects of synthetic salmon and human calcitonin. Lancet i:594–595
Clissold SP, Fitton A, Chrisp P (1991) Intranasal salmon calcitonin: a review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1:405–423
Singer FR, Alfred JP, Neer AM, Krane SM, Potts JT, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331–2338
Martin TJ (1979) Treatment of Paget's disease with calcitonins. Aust NZ J Med 9:36–43
Reginster JY, Gennari C, Mautalen C, Deroisy R, Denis D, Lecart MP, Vandalem JL, Collette J, Franchimont P (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 19:83–86
Mazzuoli GF, Minisola S, Tabolli S, Valtorta C (1983) Il fenomeno escape e plateau. In: Gennari C, Segre G (eds) The effects of calcitonin in man. Proc 1 st Int Workshop, 1982, Masson, pp 75–84
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Azria, M., Copp, D.H. & Zanelli, J.M. 25 Years of salmon calcitonin: From synthesis to therapeutic use. Calcif Tissue Int 57, 405–408 (1995). https://doi.org/10.1007/BF00301940
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00301940